Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised …
AT Shaw, TM Kim, L Crinò, C Gridelli, K Kiura… - The Lancet …, 2017 - thelancet.com
Background Ceritinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor,
which has shown robust anti-tumour efficacy, along with intracranial activity, in patients with …
which has shown robust anti-tumour efficacy, along with intracranial activity, in patients with …
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
D Planchard, B Besse, HJM Groen, PJ Souquet… - The Lancet …, 2016 - thelancet.com
Background BRAF mutations act as an oncogenic driver via the mitogen-activated protein
kinase (MAPK) pathway in non-small cell lung cancer (NSCLC). BRAF inhibition has shown …
kinase (MAPK) pathway in non-small cell lung cancer (NSCLC). BRAF inhibition has shown …
Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma,
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
[HTML][HTML] Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Background BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a
histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation …
histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation …
[HTML][HTML] Pembrolizumab for the treatment of non–small-cell lung cancer
Background We assessed the efficacy and safety of programmed cell death 1 (PD-1)
inhibition with pembrolizumab in patients with advanced non–small-cell lung cancer …
inhibition with pembrolizumab in patients with advanced non–small-cell lung cancer …
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug …
C Davis, H Naci, E Gurpinar, E Poplavska, A Pinto… - bmj, 2017 - bmj.com
Objective To determine the availability of data on overall survival and quality of life benefits
of cancer drugs approved in Europe. Design Retrospective cohort study. Setting Publicly …
of cancer drugs approved in Europe. Design Retrospective cohort study. Setting Publicly …
Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung …
Importance Lung cancer is the leading cause of cancer-related mortality in the United States
and worldwide. As systemic therapies improve, patients with lung cancer live longer and …
and worldwide. As systemic therapies improve, patients with lung cancer live longer and …
[HTML][HTML] Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
P Sharma, JP Allison - Cell, 2015 - cell.com
Research in two fronts has enabled the development of therapies that provide significant
benefit to cancer patients. One area stems from a detailed knowledge of mutations that …
benefit to cancer patients. One area stems from a detailed knowledge of mutations that …
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic …
Background The molecular profiling of patients with advanced non-small-cell lung cancer
(NSCLC) for known oncogenic drivers is recommended during routine care. Nationally …
(NSCLC) for known oncogenic drivers is recommended during routine care. Nationally …
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver
activated in multiple cancers, including non–small cell lung cancer (NSCLC), medullary …
activated in multiple cancers, including non–small cell lung cancer (NSCLC), medullary …